New Antimalarial Drug MK7602 Shows Promise & Good Tolerance in Early Trials

Early clinical trial data offer a promising step in the ongoing effort to combat malaria, a disease that continues to claim hundreds of thousands of lives each year, particularly among young children. Results from two Phase 1 studies suggest that a new drug candidate, MK-7602, is safe and well-tolerated in humans, paving the way for further investigation into its potential to address the growing challenge of drug-resistant malaria.

A Dual-Action Approach to Combating Resistance

The development of MK-7602 is a collaborative effort between the Walter and Eliza Hall Institute of Medical Research (WEHI) in Australia and MSD, known as Merck & Co., Inc. In the United States. The drug represents a “first-in-class” clinical candidate, meaning it employs a novel mechanism of action compared to existing antimalarial treatments. Crucially, MK-7602 targets two essential enzymes within the malaria parasite – Plasmodium falciparum and Plasmodium vivax – simultaneously. This dual-action strategy is designed to reduce the likelihood of parasites developing resistance, a major obstacle in malaria control and elimination efforts. As reported by The Microbiologist, this approach could be a significant advantage over current treatments.

Malaria is caused by parasites transmitted to humans through the bite of infected female Anopheles mosquitoes. According to the World Health Organization (WHO), in 2022, there were an estimated 249 million cases of malaria worldwide, resulting in 625,000 deaths. The African Region bears the greatest malaria burden, accounting for over 95% of cases and deaths. Children under five years of age are particularly vulnerable, with an estimated child dying from malaria every minute.

Phase 1 Trials: Safety and Tolerability

The initial Phase 1 clinical trials, designed primarily to assess safety and tolerability, involved a compact number of healthy volunteers. These early-stage trials do not evaluate the drug’s effectiveness against malaria infection. However, the fact that MK-7602 was well-tolerated in these studies is an encouraging sign. Wellcome is providing funding for the antimalarial drug discovery research, and notes that the compound is currently in Phase 1 clinical trials.

Phase 1 trials typically involve a gradual dose escalation to determine the maximum tolerated dose and identify any potential side effects. Researchers carefully monitor participants for adverse events and assess the drug’s pharmacokinetic properties – how the body absorbs, distributes, metabolizes, and excretes the drug. The results of these trials are essential for informing the design of subsequent Phase 2 and Phase 3 trials, which will evaluate the drug’s efficacy and optimal dosage.

Beyond Treatment: Potential for Prophylaxis and Chemo-Vaccination

The research surrounding MK-7602 extends beyond simply treating existing infections. Scientists are also exploring the possibility of developing a long-acting injectable formulation of the drug for malaria prophylaxis – preventing infection in the first place. This is particularly crucial for populations living in high-transmission areas or for travelers visiting endemic regions. The team identified chemical matter during the research programme that is amenable to long-acting administration, according to Wellcome’s funding details.

there’s a fascinating possibility of “chemo-vaccination.” This concept involves using the drug to provide extended immunological protection against infection, potentially lasting up to a year with a single injection. While still in the early stages of investigation, chemo-vaccination could offer a powerful new tool in the fight against malaria, complementing existing vaccination efforts.

Understanding Plasmepsins and the Drug’s Mechanism

MK-7602 works by inhibiting plasmepsins, enzymes crucial for the malaria parasite’s survival. Specifically, it targets plasmepsin IX and plasmepsin X. These enzymes are involved in the breakdown of hemoglobin, the protein in red blood cells, which the parasite needs for nourishment. By blocking these enzymes, MK-7602 disrupts the parasite’s life cycle and prevents it from multiplying within the host. The dual inhibition strategy is thought to craft it more tough for the parasite to develop resistance, as it would require two separate mutations to overcome the drug’s effects.

What Comes Next: Clinical Development and Regulatory Review

The successful completion of Phase 1 trials marks a significant milestone, but much operate remains to be done. The next step is to initiate Phase 2 clinical trials, which will involve a larger number of participants and will assess the drug’s efficacy in treating malaria infections. These trials will also help to refine the optimal dosage and identify any potential safety concerns that were not detected in Phase 1.

If Phase 2 trials are successful, Phase 3 trials will be conducted, typically involving thousands of participants at multiple sites. These trials are designed to confirm the drug’s efficacy and safety in a real-world setting and to provide the data needed for regulatory approval. The regulatory review process, conducted by agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), can take several years. Assuming successful completion of all clinical trials and regulatory review, MK-7602 could potentially develop into available to patients within the next few years, offering a new weapon in the fight against this devastating disease.

Ongoing surveillance of malaria parasite resistance patterns will be crucial to ensure the long-term effectiveness of MK-7602 and other antimalarial drugs. Public health organizations will continue to monitor the spread of drug-resistant strains and update treatment guidelines accordingly. The development of new antimalarial drugs, like MK-7602, is essential to stay one step ahead of the evolving parasite and protect vulnerable populations from this preventable disease.